Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. [electronic resource]
Producer: 20031030Description: 1826-45 p. digitalISSN:- 0149-2918
- Antineoplastic Agents -- administration & dosage
- Clinical Trials, Phase III as Topic
- Cost-Benefit Analysis
- Doxorubicin -- administration & dosage
- Female
- Health Care Costs -- statistics & numerical data
- Humans
- Infusions, Intravenous
- Italy -- epidemiology
- Liposomes
- Ovarian Neoplasms -- drug therapy
- Polyethylene Glycols
- Randomized Controlled Trials as Topic
- Topotecan -- adverse effects
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.